Moscow's pharmaceutical industry is represented by more than 30 large and medium-sized enterprises. Four of them have been awarded the status of industrial complexes, which allows them to ease their tax burden and reduce payments to the city budget to 20%.
In 2016, the total value of pharmaceutical goods shipped by the Moscow-based enterprises was worth 46 billion rubles. These products enjoy strong demand in Russia and abroad. The share of Moscow in the overall Russian export of pharmaceuticals accounted for 24%.
Moscow's pharmaceutical enterprises provide high-paid technology-driven jobs to 8,400 people. Since 2012, the average salary in the industry has grown by 70%. In 2016, the average salary reached 86,600 rubles, which is 1.8 times higher than the national average for the industry.
“The pharmaceutical industry is among most important ones for the city; it is highly advanced technologically and has a significant social component. I am happy to say that the industry is developing dynamically. Over the past three years, the production has expanded by 30% in volume,” said Alexei Fursin, the head of the Moscow Department of Science, Industrial Policy and Entrepreneurship.
According to Fursin, state procurement contracts play a major role in this industry as they provide manufacturers with guaranteed sales. In 2016, Moscow's share of all state pharmaceuticals procurement contracts in Russia was 23%. Moreover, the Government of Moscow provides incentives to pharmaceutical manufacturers, thus driving their localization and business development initiatives. Many manufacturers who spoke at the event consider the city's support substantial.
Alexei Alyokhin, the director for medical and pharmaceuticals industry development at the Ministry of Industry and Trade, reminded the audience of the task set out by the federal government: to increase the domestic production of essential medications to 90% of the demand. He believes that Russian manufacturers are up to the challenge as their current share of such medications is 81.5%. In general, every second pill in Russia is made locally.
He added that Moscow as the largest customer in the industry provides an attractive location for manufacturing, because the city offers top competencies and is equipped with highly professional workforce.
Many local enterprises have strong R&D departments focused on the manufacturing of original medications. Moscow Endocrine Plant obtained four new registration certificates for its products in 2016, and two more in 2017. According to Natalia Ovsyankina, the deputy director of the plant, her organization has recently signed six state procurement contracts and registered five new patents.
Biotiki Medical Research and Manufacturing Complex is focused exceptionally on original medications. Yaroslav Nartsissov, the CEO of Biotiki, said he consciously opted for this approach. In his view, although mass manufacturing of generics yields good profits, it also creates system-wide global problems that inhibit the industry's growth.
Alexei Fursin: Pharmaceutical Manufacturing in Moscow Grew 30% in 3 Years
Local pharmaceutical manufacturers held an industry meeting today at the congress center of Technopolis Moscow. The event continued a series of industry-specific meetings launched by the Moscow Department of Science, Industrial Policy and Entrepreneurship in December 2016.
05 июля 2017
03 июля 2017